ABSTRACT

We reported a case of atrophic nonunion after humeral shaft fracture in a patient with severe psychiatric disorders that advised against hospital admission and surgery. He was treated with teriparatide (recombinant human 1-34 parathyroid hormon) [rh (1-34) PTH] in daily subcutaneous injections. After 4 months of treatment, healing of nonunion, associated to clinical improvement and functional recovery of the patient, was observed. No other intervention was required, and no side effects attributable to the drug occurred.

1. INTRODUCTION

Occurrence of nonunion in the humeral shaft increases morbidity and decreases functional capacity. Multiple procedures may be used to achieve healing of nonunion, including open reduction, internal or plate fixation, or use of autologous bone grafting, allograft, or demineralized bone matrix. Adequate treatment of nonunion requires an understanding of its biomechanical and biological causes. Hypertrophic nonunions may show exuberant callus formation around the fracture site. As they are biologically active, they will heal adequately once deformities are corrected and stability is improved. Synovial nonunions, covered with cartilaginous tissue, and infected nonunions required removal of devitalized tissue and adequate stabilization. Finally, in atrophic nonunions with little or no bone callus formation osteogenic capacity must be restored by bone grafting [1]. It is in this type of nonunion where pharmacological agents with osteogenic capacity could have an attractive role in the future.

2. METHODS

The patient was a 39-year-old Caucasian male, smoker of 10 - 15 cigarettes daily, diagnosed with paranoid schizophrenia and depressive syndrome that was being treated with olanzapine 5 mg/day, lormetazepam 1 mg/day, clorazepate dipotassium 45 mg/day in 3 doses, and lorazepam 3 mg/day in 3 doses. He had cocaine and alcohol addiction problems and was voluntarily participating in a methadone treatment program. The patient sustained a multifragmented fracture of the right humerus [AO/Association for the Study of Internal Fixation (ASIF) type C] (Figure 1) after an accidental fall at home. There were no associated neurovascular symptoms.

Upon admission, normal results were reported for the following laboratory parameters, among others: total alkaline phosphatase and its bone fraction, liver function tests, including negative serologic tests for hepatitis B, C and HIV, serum creatinine, ionic calcium, erythrocyte sedimentation rate, C reactive protein, 25-hydroxy-vitamin D, parathyroid hormone, prolactin, testosterone and 24-hour urinary calcium. Dual energy X-ray absorptiometry (DXA scan) revealed normal values (lumbar spine DXA scan T score-0,9; total hip T score-0,8; femoral T score-0,9).

Based on the clinical condition and the patient’s own decision, treatment consisted of immobilization with plaster, followed by a functional brace. At 7 months, patient reported pain and mobility in the fracture site, and Xrays showed no signs of union (Figure 2). Patient refused use of surgery, but accepted an empirical treatment with teriparatide [rh (1-34) PTH] 20 μg as a subcutaneous daily injection.

3. RESULTS

At 4 months of treatment, X-ray images showed bone union (Figure 3). This was associated to disappearance

of pain and complete functional recovery which allowed the patient to return to his usual activities (Figure 4). Results of laboratory tests performed during treatment were normal, showing no complication attributable to the drug. No side effects attributable to the drug were observed during treatment and subsequent laboratory tests continued to be normal.

In accordance with Spanish law regarding data protection (Organic Law 15/1999), the patient authorized his clinical data to be published in a scientific journal and signed inform consent.

4. DISCUSSION

Uncomplicated humeral shaft fractures may be ade-

quately treated with non-surgical procedures [2-7]. In certain situations such as open fractures, fractures associated to vascular and/or nerve lesions, and bilateral or multiple fractures, there is a clear indication for surgery consisting of osteosynthesis with either a plate or an intramedullary nail [7,8]. However there are a number of clinical situations where treatment selection is difficult because special attention should be paid to characteristics of the patients, as occurs when these are poorly cooperative [9,10].

This patient, based on his severe psychiatric disorders advising against hospital admission and his own will, was place a functional brace despite the fact that the fracture affected the proximal third of the dyaphysis with a long oblique line, and risk of delayed union was therefore high [11].

With conservative treatment, union of humeral shaft fractures occurs in approximately 16 weeks [12]. Incidence of humeral shaft nonunion ranges from 0% and 8% after conservative treatment of these fractures and from 0% and 13% after surgical treatment. Atrophic nonunions are most common [13]. A number of risk factors have been reported to be associated to nonunion of humeral fractures [13-16] (Table 1), including cigarette smoking. According to data from animal models, certain prostaglandins (E and F2α) are involved in the early stages of the union process [17]. Inhibition of cyclooxygenase (COX) activity by nonselective nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX2 inhibitors decreases levels of such prostaglandins [17,18]. It appears that this inhibition would be related to the time of exposure to the drug and that these negative effects would be reversible after short treatment periods [19]. The role of NSAIDs in delaying the union process in humans is currently controversial, and there are reports advising against their use in close temporal proximity to a fracture [20-22].

Seven months after the fracture, the patient had clinical symptoms and radiographic signs of nonunion, and off-label treatment with teriparatide was therefore started. Teriparatide is approved by the Food and Drug Administration and the European Medicines Agency to treat osteoporosis in post-menopausal women and men at high risk of fracture, and in glucocorticoid-induced osteoporosis. Teriparatide stimulates bone formation, improving some macro and microarchitectural characteristic of bone [23], and it appears to have a potential to accelerate fracture callus formation and remodeling during bone repair. It may accelerate bone healing through stimulation of the Wnt path system, among others [24]. This effect was shown in a clinical trial conducted in distal radial fractures in osteoporotic postmenopausal women. Fracture healing was achieved 2 weeks earlier in the group treated with teriparatide 20 µg daily, the approved dose for the treatment of osteoporosis, as compared to the placebo group [25]. There are also clinical reports of treatment of different fracture models [26,27] and cases of delayed union and nonunion [28-30]. We recently reported a clinical case of healing of atrophic nonunion of the humeral shaft following osteosynthesis with flexible intramedullary nailing in which 3 months of teriparatide treatment achieved full functional recovery [31].

In the reported case, after 4 months of treatment with teriparatide and with no other intervention that could influence the final clinical outcome, was related with a radiographic image of union associated with full functional recovery, which—in author’s opinion—was causally related to the treatment administered.

Systemic administration of drugs to accelerate fracture union is an attractive option, which becomes particularly relevant in situations in which a high surgical risk exists. The clinical trial conducted by Aspenberg et al. [25] in distal radial fractures in women with osteoporosis support this accelerating effect of union of teriparatide.

Table 1. Risk factors related with nonunion in humeral fractures.

Use of teriparatide for the treatment of nonunion, particularly atrophic nonunion, is based on its osteogenic effect and has been demonstrated in case series. In the author’s opinion and based on currently available data, teriparatide could be an excellent therapeutic option, alone or combined with other interventions, to achieve healing of nonunion, particularly when an increased surgical risk exists due to fracture location or clinical characteristics of the patient. However, future clinical trials will offer the possibility to obtain data that will make the registration as an accelerator for fracture healing possible.

5. ACKNOWLEDGEMENTS

The author thanks Dr. Fernando Marín for his good advice when evaluating these results.

REFERENCES

NOTES

^*Ángel Oteo-Álvaro was a member of Eli Lilly Spain Speakers’ Bureau. María Teresa Marín doesn’t have conflict of interest. Author, their immediate family, and any research foundation with which they are affiliated did not receive any financial payments or other benefits from any commercial entity related to the subject of this article. Author states that this clinical case report did not receive outside funding or grants.